AstraZeneca PLC ADR (AZN)

54.69
+1.45(+2.72%)
After Hours
54.69
0.00(0.00%)
- Real-time Data
  • Volume:
    7,831,454
  • Day's Range:
    53.24 - 54.94
  • 52 wk Range:
    52.65 - 71.70

AZN Overview

Prev. Close
53.24
Day's Range
53.24-54.94
Revenue
41.49B
Open
53.26
52 wk Range
52.65-71.7
EPS
-0.816
Volume
7,831,454
Market Cap
167.55B
Dividend (Yield)
1.42
(2.67%)
Average Volume (3m)
6,461,822
P/E Ratio
-159.09
Beta
0.119
1-Year Change
-9.33%
Shares Outstanding
1,549,495,319
Next Earnings Date
Nov 10, 2022
What is your sentiment on AstraZeneca ADR?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC ADR News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

AstraZeneca PLC ADR Analysis

AstraZeneca PLC ADR Company Profile

AstraZeneca PLC ADR Company Profile

Employees
83100

AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyNeutralSellNeutral
Technical IndicatorsNeutralStrong BuyStrong BuyStrong SellSell
SummaryNeutralStrong BuyBuyStrong SellNeutral
  • do not buy this stock, it's a trap
    1
    • Junk like pfizer
      1
      • why is this stock so stagnant? even with good news it seems to drop.
        0
        • Japan, AstraZeneca agree on 120 mil. COVID-19 vaccine dose supply KYODO NEWS - 2 hours ago - 21:49 | All, Japan, Coronavirus
          1
          • I dont get how this company pumps out good news and a potential merger and the stock moves by pennies. what will it take for this stock to jump?
            0
        • Get into it before FDA approves vaccine
          2
          • is it too late to get in?
            2
            • Not really man,Its just the beginning.Its gonna be late 3 weeks after.
              0
            • I think it's a good time. this stock is stable historically and pays dividends. I bought at 62 so I'm down big but have faith it will be good long term.
              0
            • 0